Page 4 - Ohnson Johnson News Today

(Bloomberg) -- Johnson & Johnson shares tumbled after the company said profit margins in its medical device and technology unit fell last quarter and drug sales will be lower in the second half of the year than the first.Most Read from BloombergChina Weighs Stock Market Rescue Package Backed by $278 BillionNetflix Pays $5 Billion for ‘Raw’ in Bet on Live EventsAn Isolated Israel Doubles Down on War in Gaza — At All CostsIndia Tops Hong Kong as World’s Fourth-Larg...

The deal includes 42 states and Washington, D.C. The company tentatively agreed to pay about $700 million to settle the states' claims, according to the Wall Street Journal. “Consistent with the plan we outlined last year, the company continues to pursue several paths to achieve a comprehensive and final resolution of the talc litigation," Erik Haas, J&J's worldwide vice president of litigation, said in a statement. The settlement does not extend to private plaintiff...

The firm is still facing claims from thousands of customers who allege its talc-based products caused cancer.

JNJ earnings call for the period ending December 31, 2023.

Johnson & Johnson confirms an agreement in principle with 43 states to resolve talc claims. The deal reportedly amounts to $700 million.

(Bloomberg) -- US stocks eked out a gain Tuesday, setting fresh closing highs ahead of an onslaught of company reports that promise insight into the state of the global economy. Most Read from BloombergChina Weighs Stock Market Rescue Package Backed by $278 BillionApple Dials Back Car’s Self-Driving Features and Delays Launch to 2028An Isolated Israel Doubles Down on War in Gaza — At All CostsNetflix Pays $5 Billion for ‘Raw’ in Bet on Live EventsTurkey Approves Swede...

These stocks may help you win in 2024 -- no matter what the market does.

This company is currently firing on all cylinders.

Not every dividend stock is created equal, and these two far exceed Walgreens Boots Alliance.

Sen. Bernie Sanders plans a Jan. 31 vote to subpoena Pharma CEOs for a drug pricing hearing after they declined last year, citing "unacceptable" refusal and questioning high costs compared to other countries.